Quantinno Capital Management LP Purchases 188,287 Shares of Zoetis Inc. $ZTS

Quantinno Capital Management LP increased its position in shares of Zoetis Inc. (NYSE:ZTS) by 132.1% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 330,839 shares of the company’s stock after acquiring an additional 188,287 shares during the period. Quantinno Capital Management LP’s holdings in Zoetis were worth $39,109,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in the company. Vanguard Group Inc. lifted its stake in Zoetis by 12.9% during the fourth quarter. Vanguard Group Inc. now owns 47,780,974 shares of the company’s stock worth $6,011,802,000 after purchasing an additional 5,474,210 shares during the last quarter. J. Stern & Co. LLP increased its stake in shares of Zoetis by 12,431.2% in the 4th quarter. J. Stern & Co. LLP now owns 24,069,492 shares of the company’s stock valued at $3,028,423,000 after purchasing an additional 23,877,416 shares during the last quarter. State Street Corp raised its holdings in shares of Zoetis by 0.8% during the 4th quarter. State Street Corp now owns 19,796,891 shares of the company’s stock worth $2,490,845,000 after buying an additional 149,382 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Zoetis by 1.7% during the 4th quarter. Geode Capital Management LLC now owns 11,327,679 shares of the company’s stock worth $1,420,294,000 after buying an additional 189,235 shares in the last quarter. Finally, Norges Bank acquired a new position in shares of Zoetis during the 4th quarter worth $734,425,000. 92.80% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several analysts recently weighed in on the company. Stifel Nicolaus reduced their price objective on Zoetis from $95.00 to $85.00 and set a “hold” rating on the stock in a research note on Friday, June 26th. Argus reissued a “hold” rating on shares of Zoetis in a research note on Wednesday, May 27th. JPMorgan Chase & Co. dropped their target price on shares of Zoetis from $190.00 to $130.00 and set an “overweight” rating for the company in a report on Friday, May 8th. Weiss Ratings downgraded shares of Zoetis from a “sell (d+)” rating to a “sell (d)” rating in a research note on Friday, June 12th. Finally, Barclays decreased their price target on shares of Zoetis from $136.00 to $85.00 and set an “equal weight” rating on the stock in a report on Wednesday, July 1st. Eight investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $118.33.

Zoetis Trading Down 2.4%

NYSE ZTS opened at $76.04 on Friday. The company has a market cap of $31.88 billion, a price-to-earnings ratio of 12.61, a price-to-earnings-growth ratio of 1.22 and a beta of 0.75. Zoetis Inc. has a twelve month low of $71.47 and a twelve month high of $160.48. The company has a quick ratio of 1.91, a current ratio of 3.15 and a debt-to-equity ratio of 2.80. The business’s fifty day moving average is $77.13 and its 200 day moving average is $102.66.

Zoetis (NYSE:ZTS) last issued its earnings results on Thursday, May 7th. The company reported $1.53 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). The firm had revenue of $2.26 billion during the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a return on equity of 66.85% and a net margin of 27.80%.Zoetis’s revenue for the quarter was up 2.9% on a year-over-year basis. During the same period in the previous year, the company earned $1.48 EPS. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. As a group, sell-side analysts expect that Zoetis Inc. will post 6.87 EPS for the current fiscal year.

Zoetis Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Monday, July 20th will be paid a $0.53 dividend. The ex-dividend date of this dividend is Monday, July 20th. This represents a $2.12 annualized dividend and a dividend yield of 2.8%. Zoetis’s dividend payout ratio is currently 35.16%.

Insider Activity

In other Zoetis news, Director Paul Bisaro acquired 2,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 13th. The stock was acquired at an average price of $75.88 per share, for a total transaction of $151,760.00. Following the acquisition, the director directly owned 27,862 shares in the company, valued at $2,114,168.56. This represents a 7.73% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Frank A. Damelio acquired 6,650 shares of the company’s stock in a transaction that occurred on Wednesday, May 13th. The stock was acquired at an average price of $75.39 per share, with a total value of $501,343.50. Following the acquisition, the director owned 21,458 shares in the company, valued at $1,617,718.62. The trade was a 44.91% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders bought 11,650 shares of company stock valued at $886,384 over the last quarter. 0.22% of the stock is owned by company insiders.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.